This inventor holds 1 USPTO granted patent. Top assignee: Sloan-Kettering Institute for Cancer Research. Active years: 2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2002
Title: Ken Rivlin: Innovator in Cancer Research
Introduction
Ken Rivlin is a prominent inventor based in New York, NY, known for his significant contributions to cancer research. With one patent to his name, Rivlin is dedicated to advancing therapeutic methodologies through innovative biotechnology.
Latest Patents
Rivlin’s patent, titled "Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods," focuses on recombinant antibody constructs that incorporate variable regions of anti-G antibodies' heavy and light chains. These constructs can be combined with labels, such as radiolabels, or proteins like streptavidin. They are designed for both imaging and therapeutic applications. Additionally, these antibody constructs can be introduced into T cells, creating targeted populations aimed at G-producing tumor cells, marking a significant step in cancer treatment options.
Career Highlights
Working at the Sloan Kettering Institute for Cancer Research, Rivlin is part of an esteemed organization that focuses on groundbreaking research in oncology. His work aims to innovate the way cancer is diagnosed and treated, utilizing advanced biotechnological approaches.
Collaborations
Throughout his career, Rivlin has collaborated with notable professionals in the field, including Nai-Kong V Cheung and Steven M Larson. These relationships highlight the importance of teamwork in scientific advancements and the shared goal of improving patient outcomes through innovative solutions.
Conclusion
Ken Rivlin stands as an influential figure in cancer research. His patented work showcases the potential of combining biotechnology with therapeutic approaches to improve treatment efficacy. Rivlin's innovative mindset and dedication contribute to the ongoing fight against cancer, paving the way for future breakthroughs in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
